Drug intelligence / Profile preview

BI 425809 + memantine

Development stage: Unknown
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

**BI 425809 + memantine** is a combination of two small molecule pharmaceuticals. BI 425809 is a selective inhibitor of Glycine transporter-1, investigated for improving cognition in patients with schizophrenia[2][4]. Memantine is an approved NMDA receptor antagonist used for moderate to severe Alzheimer's dementia[3][5]. As a combination, these drugs are studied to assess pharmacokinetics, safety, and potential synergistic effects on cognitive function and neurological health[1]. The developer and sponsor of studies involving this combination is Boehringer Ingelheim[1][2][4].

Brand names: NamendaAxuraEbixaMarixinoNemdatine
Other names: BI 425809 + memantine

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)SLC6A9 (Glycine transporter type 1)

Beyond the preview

Go deeper on BI 425809 + memantine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 425809 + memantine.

Explore the full profile